Immune checkpoint inhibitors have revolutionized cancer treatment, but not all patients respond equally. Now, researchers from Japan have explored why two anti-PD-L1 antibodies, which target the same immune pathway, produce vastly different therapeutic outcomes in a mouse cancer model. They found that an immune mechanism known as antibody-dependent cellular cytotoxicity can inadvertently destroy antitumor immune cells. These findings underscore the importance of selecting antibody drugs that minimize off-target effects to improve the efficacy of immunotherapy.

Chemotherapy-induced nausea and vomiting can severely impact patients’ quality of life and treatment adherence. In a major clinical trial, researchers from Japan tested whether a low, 5 mg dose of olanzapine taken at home after chemotherapy could reduce these side effects without causing heavy sedation. The study found that this approach significantly improved outcomes compared to placebo, offering a safer, more affordable strategy that could reshape supportive cancer care, especially in outpatient and resource-limited settings.

Singapore-led study shows specialised support cells in the gut form direct, neuron-like connections to deliver precise instructions to stem cells; 

Overturns long-held beliefs about how gut cells communicate; 

Opens new paths for treating colon cancer and IBD